Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects

Abstract A pharmacokinetics (PK)/pharmacodynamics (PD) study (EudraCT number 2015‐002966‐21) was conducted to investigate the biosimilarity of Pelmeg® (pegfilgrastim), a biosimilar to EU‐authorized Neulasta®, which is used in the clinic for prevention of chemotherapy‐induced neutropenia. The single‐...

Full description

Bibliographic Details
Main Authors: Karsten Roth, Dirk Lehnick, Hendrik Wessels, Josef Höfler, Barbara Gastl, Ruediger Jankowsky
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Pharmacology Research & Perspectives
Subjects:
biosimilar
filgrastim
myelosuppressive chemotherapy
Neulasta
neutropenia
oncology
Online Access:https://doi.org/10.1002/prp2.503

Internet

https://doi.org/10.1002/prp2.503

Similar Items